Nvidia launches BioNeMo Agent Toolkit as 50 companies adopt AI life sciences platform

Nvidia Corp. on Tuesday released the BioNeMo Agent Toolkit, a suite of domain-specific tools that lets AI agents perform scientific tasks across biology, chemistry and drug discovery, with more than 50 companies already adopting the platform.

"Frontier models are the brains. BioNeMo is the scientific toolbox," Jensen Huang, founder and chief executive officer of Nvidia, said in a statement. "For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows."

The toolkit integrates Nvidia's life sciences libraries, NIM microservices, Parabricks genomics analysis tools and Nemotron reasoning models into agent-callable skills for tasks including protein structure prediction, molecular docking, generative chemistry and biomarker discovery. The University of Washington's Institute for Protein Design reported 2x faster runtimes for RosettaFold3 using the platform compared with the prior-generation model, according to Nvidia.

Life sciences represents one of the largest addressable markets for AI infrastructure, with global scientific research and development spending reaching $3.8 trillion and annual pharmaceutical budgets approaching $300 billion, Nvidia said. The toolkit allows general-purpose AI agents to be transformed into specialized scientific agents in minutes, enabling researchers to iterate faster between hypothesis and experimental validation.

Ecosystem adoption spans labs, data platforms and pharma

Sigmatic Sciences, a Sapio Sciences company, said it has integrated the BioNeMo Agent Toolkit within its SigmaticOS operating system, which orchestrates more than 300 specialized scientific agents across data, models and laboratory automation. The platform connects Nvidia's biological AI models — including OpenFold3 and Boltz-2 for biomolecular structure prediction and RNApro for RNA analysis — with proprietary experimental data, electronic lab notebook systems from Sapio Sciences and scientific literature from Elsevier.

Simulations Plus is building the agentic layer of its Composer platform using the BioNeMo Agent Toolkit and collaborating with Nvidia on nvQSP, a CUDA-optimized solver for quantitative systems pharmacology. "By combining the NVIDIA BioNeMo Agent Toolkit with our scientific engines, we're building agents that seek to accelerate scientific work while preserving the rigor required for critical development decisions," Erik Guffrey, co-chief product and technology officer of Simulations Plus, said.

Scientific data platforms including Benchling, Databricks, Snowflake and Seqera are integrating BioNeMo skills to connect data systems with AI-powered analysis. Diagnostics and pharmaceutical companies Lilly and Natera are using the toolkit to scale agentic workflows across discovery and clinical insight. Computer-aided drug discovery software providers Dassault Systèmes, Cadence and Schrodinger are incorporating the toolkit's capabilities, allowing agents to orchestrate molecular generation and docking within existing scientific applications. Lab automation companies including Thermo Fisher, Tecan and Automata are connecting physical laboratory systems with BioNeMo-powered computational discovery.

Nvidia shares have gained more than 150 percent over the past year as data center revenue surged on AI infrastructure spending. The BioNeMo expansion into life sciences opens a new vertical that could sustain demand for Nvidia's accelerated computing hardware beyond the initial cloud buildout phase. With pharmaceutical companies spending nearly $300 billion annually on research and development, even a fraction of that budget shifting toward AI-powered discovery represents a material revenue opportunity for Nvidia's data center segment, which generated $47.5 billion in the most recent fiscal year.

This article is for informational purposes only and does not constitute investment advice.